Europe should seriously consider the 'accelerator' concept to foster the sustainability of its biotech companies.
which has started or re-started six companies that are each developing medical devices for interventional cardiology products. The team running Advanced Technologies includes seasoned investors, cardiologists and clinicians, all of whom have clear roles to play in speeding up the development, clinical adoption and commercialization of cardiovascular devices and hence in providing expedited investment and business exits.
More accelerators are on the way. A consortium of large pharmaceutical firms is said to be considering creating one in the Cambridge, Massachusetts biotech cluster. And another may be built in the San Diego biotech cluster.
Oddly, just as accelerators are finding new ways to make the milieu for new US firms more encouraging and less risky, the opposite may be true in Europe. In the United States and the more advanced parts of Europe, the rate of formation of new companies has slowed in recent years. Consequently, a large proportion of the new European foundlings are arising in nations or regions that are themselves new to biotech. Often, there are precious few biotech-relevant resources in these locations, beyond a bit of seed money: there are no substantial finance streams, no management skills, no biotech-experienced support infrastructure of lawyers, accountants and consultants.
Such environments are precisely the opposite of accelerators, and are likely to have precisely the opposite effect. Global competition and technology supercession means that biotech firms need to have a 'Red Queen' mentality. But trying to 'run as fast as you can just to stay still' is difficult if you are wading through mud.
The lesson for companies in nations with new, fledgling biotech sectors is that they need to reach out beyond national borders to management and financiers in other, more established biotech clusters. It's important to work with these experienced executives and investors because they are familiar with the idiosyncrasies and protracted timelines of life science ventures and they have the requisite historical and international perspective to place new biotech platforms or products in their proper global competitive context.
In this respect, the Accelerator model looks particularly interesting. Given the difficulty of pooling investors and management expertise and the relative scarcity of truly globally competitive ventures emerging at the national level, perhaps a pan-European accelerator could be an effective approach. Certainly, if European centers of scientific excellence don't want much of their first-class intellectual property to be hamstrung by underfunding, naive management and unsupportive surroundings, they should seriously consider the concept.
Europe doesn't need more biotech ventures; it needs more successful ones. And starting biotech accelerators would be one means of bringing together the sort of expertise and funding that could increase the chances that that would happen.
E D I T O R I A L

